Shares of NewLink Genetics Corp. (NASDAQ:NLNK) dropped 1.1% on Friday . The stock traded as low as $10.07 and last traded at $10.20, with a volume of 150,225 shares traded. The stock had previously closed at $10.31.

NLNK has been the topic of several recent research reports. Robert W. Baird restated an “outperform” rating and issued a $23.00 price target (down previously from $27.00) on shares of NewLink Genetics Corp. in a research note on Tuesday, May 10th. Zacks Investment Research upgraded NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, July 5th. Mizuho cut their price target on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Stifel Nicolaus cut their price target on NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Finally, Jefferies Group restated a “hold” rating and issued a $10.00 price target on shares of NewLink Genetics Corp. in a research note on Wednesday, May 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. NewLink Genetics Corp. presently has a consensus rating of “Hold” and a consensus target price of $23.29.

The firm’s market cap is $287.08 million. The company’s 50 day moving average is $10.59 and its 200 day moving average is $14.06.

NewLink Genetics Corp. (NASDAQ:NLNK) last posted its quarterly earnings results on Friday, July 29th. The company reported ($1.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.35. Analysts anticipate that NewLink Genetics Corp. will post ($3.06) earnings per share for the current year.

A hedge fund recently raised its stake in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP increased its stake in shares of NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned about 0.17% of NewLink Genetics Corp. worth $1,765,000 as of its most recent SEC filing.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.